<DOC>
	<DOCNO>NCT00836173</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad ; rituximab , ifosfamide , carboplatin etoposide ( RICE ) follow gallium nitrate , rituximab dexamethasone ( GARD ) diffuse large B cell lymphoma . This research do try find effective treatment type cancer . We want know whether treatment rituximab , ifosfamide , carboplatin etoposide ( RICE ) follow gallium nitrate , rituximab dexamethasone ( GARD ) improve survival . Rituximab , ifosfamide , carboplatin etoposide ( RICE ) part usual treatment diffuse large B-cell lymphoma . Gallium nitrate , rituximab dexamethasone ( GARD ) lymphoma experimental .</brief_summary>
	<brief_title>Rituximab , Ifosfamide , Carboplatin , Etoposide ( RICE ) Followed Gallium Nitrate , Rituximab Dexamethasone ( GARD ) Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This Phase 2 trial evaluate efficacy add combination GaRD x 2 cycle follow 3 cycle standard salvage regimen RICE treatment relapse refractory diffuse , large B-cell lymphoma ( DLBCL ) . The study include patient relapse 1 prior treatment regimen refractory initial chemotherapy . We evaluate patient response rate ( partial complete ) , toxicity , well overall progression free survival . Eligible patient receive standard RICE x 3 cycle follow GaRD x 2 cycle . Patients would otherwise eligible , may proceed autologous stem cell transplant ( ASCT ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Gallium nitrate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must histologically cytologically confirm diffuse , large Bcell lymphoma ( WHO classification diffuse large Bcell lymphoma mediastinal large Bcell lymphoma ) , immunoblastic B cell lymphoma Burkitts lymphoma . Transformed , large Bcell lymphoma exclude . Must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 10 mm spiral CT scan . Must refractory initial therapy disease relapse prior therapy must least 3 week post treatment prior chemotherapy radiation therapy . Age &gt; 18 year . Life expectancy &gt; 24 week SWOG performance status &lt; 1 ( Karnofsky &gt; 80 % ) . Must normal organ function ( impaired marrow function ) define : leukocyte &gt; equal 1,500/mcL absolute neutrophil count &gt; equal 1,000/mcL platelet &gt; equal 50,000/mcL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) &lt; equal 2.5 X institutional upper limit normal unless due lymphoma involvement creatinine clearance &gt; equal 60 mL/min Must agree become pregnant duration study participation . Ability understand willingness sign write informed consent document . Patients chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior enter study . Follicular Bcell lymphoma , small lymphocytic lymphoma , chronic lymphocytic leukemia , lymphoblastic lymphoma Tcell lymphoma . Patients may receive investigational agent , within trial previous 4 week . Patients know CNS metastasis exclude clinical trial . History allergic reaction attribute compound similar chemical biologic composition gallium nitrate , rituximab , dexamethasone , ifosfamide , carboplatin , and/or etoposide . Prior therapy gallium nitrate , ifosfamide , carboplatin and/or etoposide Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman nurse exclude study . Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction RICE and/or GaRD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CARBOPLATIN</keyword>
	<keyword>DEXAMETHASONE</keyword>
	<keyword>DIFFUSE LARGE B-CELL LYMPHOMA</keyword>
	<keyword>ETOPOSIDE</keyword>
	<keyword>GALLIUM NITRATE</keyword>
	<keyword>IFOSFAMIDE</keyword>
	<keyword>PHASE II</keyword>
	<keyword>RELAPSED OR REFRACTORY</keyword>
	<keyword>RITUXIMAB</keyword>
</DOC>